FDA greenlights BITT’s Phase I trial of BITT2101 for Non-Hodgkin’s lymphomas

Boston Immune Technologies and Therapeutics, Inc. (BITT), a pioneering clinical-stage biotech company, has announced the US Food and Drug Administration's (FDA) clearance for the Investigational ... Read More